ArticleFrontiers in immunology2026
Tuberculous meningoencephalitis concurrent with autoimmune glial fibrillary acidic protein astrocytopathy: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculous meningoencephalitis and autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy display similar clinical features, cerebrospinal fluid (CSF) profiles, and neuroimaging patterns, which contribute to a high rate of misdiagnosis. Co-existence of these two diseases is extremely rare, and the clinical characteristics of this overlap syndrome remain poorly understood. Case presentation: A 67-year-old male patient was admitted with symptoms of fever, cognitive slowing, and limb weakness. Brain magnetic resonance imaging (MRI) showed multiple parenchymal signal abnormalities and leptomeningeal enhancement, associated with markedly increased intracranial pressure. The CSF showed pleocytosis, increased protein, decreased glucose, and decreased chloride levels. Simultaneously, a positive result was obtained from GeneXpert MTB/RIF, which is a diagnostic tool for tuberculous meningoencephalitis. In addition, GFAP antibodies were positive in both serum and CSF. Thus, a diagnosis of tuberculous meningoencephalitis and GFAP astrocytopathy was made. The patient showed significant clinical improvement after receiving antitubercular drugs and corticosteroids. Repeat MRI after steroid discontinuation demonstrated an increase in abnormal enhancing lesions. The lesions improved after glucocorticoid reintroduction. Conclusion: Tuberculous meningoencephalitis and GFAP astrocytopathy represent a rare overlap syndrome, and these cases are potentially susceptible to therapeutic paradoxical reactions, which are visible on imaging studies. Therapy for these cases involves concomitant anti-infective and immunomodulatory therapy, with consideration for the timing of steroid tapering and discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.